Immunosuppressive treatment of ocular myasthenia gravis

BioDrugs

Volumn 15, Issue 6, 2001, Pages 369-378

  Tackenberg, Björn ^a   Hemmer, Bernhard ^a   Oertel, Wolfgang H ^a   Sommer, Norbert ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; PREDNISONE; PYRIDOSTIGMINE;

CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MYASTHENIA GRAVIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; SIDE EFFECT; THYMECTOMY; TREATMENT PLANNING; WEIGHT GAIN;

EID: 0034906985     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200115060-00003     Document Type: Review

References (70)

1. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark: a longitudinal and comprehensive population survey. Arch Neurol 1991; 48; 733-9
2. Tola MR, Granieri E, Paolino E, et al. Epidemiological study of myasthenia gravis in the province of Ferrara, Italy. J Neurol 1989; 236;388-90
3. Storm-Mathisen A. Epidemiology of myasthenia gravis in Norway. Acta Neurol Scand 1984; 70; 274-84
4. Yu YL, Hawkins BR, Ip MSM, et al. Myasthenia gravis in Hong Kong Chinese, 1 : epidemiology and adult disease. Acta Neurol Scand 1992; 86: 113-9
5. Robertson NP, Deans J, Compston DAS. Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England. J Neurol Neurosurg Psychiatry 1998; 65: 492-6
6. Thomas CE, Mayer SA, Gungor BS, et al. Myasthenie crisis: Clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 1997; 48: 1253-60
7. Beekman R, Kuks JBM, Oosterhuis HJGH. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol 1997;244: 112-8
8. Osserman KE, Genkins G. Studies in myasthenia gravis: review of a twenty years experience in over 1200 patients. Mt Sinai JMed 1971:38:497-537
9. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 1997; 62: 156-62
10. Evoli A, Tonali P. Bartoccioni E, et al. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988; 77:31-5
11. Oosterhuis HJGH. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry 1989; 52: 1121-7
12. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 val-idated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry 1985; 48: 1246-52
13. Limburg PC, The TH, Hummerl-Tappel E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis, part 1 : relation to clinical parameters in 250 patients. J Neurol Sei 1983; 58: 357-70
14. Toyka KV, Heininger K. Acetylcholine-receptor antibodies in the diagnosis of myasthenia gravis. Dtsch Med Wochenschr 1986; 111: 1435-9
15. Schlimm F. Wiethölter H, Fateh-Moghadam A, et al. Thymectomy in myasthenia gravis with pure motor ocular symptoms. J Neurol Neurosurg Psychiatry 1985; 48: 332-7
16. Evoli A, Tonali P, Bartocchioni E, et al. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol Scand 1988:77:31-5
17. Kelly Jr JJ, Daube JR. Lennon VA, et al. The laboratory diagnosis of mild myasthenia gravis. Ann Neurol 1982; 12:238-42
18. Francis 1C, Nicholson GA, Kappagoda MB. An evaluation of signs in ocular myasthenia gravis and correlation with acetylcholine receptor antibodies. Aust N Z J Ophthalmol 1985: 13: 395-9
19. Sommer N, Melms A, Weller M, et al. Ocular myasthenia gravis: a critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993; 84: 309-33
20. Moorthy G, Behrens MM, Drachman DB, et al. Ocular pseudomyasthenia or ocular myasthenia 'plus': a warning to clinicians. Neurology 1989; 39: 1150-4
21. Newsom-Davis J. Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis. Muscle Nerve 1990; 13: 1186
22. Seybold ME. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43: 842-3
23. Daroff RB. The office Tensilon test for ocular myasthenia gravis. Arch Neurol 1986; 43: 843-4
24. Sanders DB, Howard JF. Single-fiber electromyography in myasthenia gravis. Muscle Nerve 1986; 9: 809-19
25. Newsom-Davis J. Autoimmunity in neuromuscular disease. Ann NY Acad Sei 1988; 540: 25-38
26. Newsom-Davis J. Diseases of the neuromuscular junction. In: Asbury AK, McKhann GM, McDonald WI, editors. Diseases of the nervous system. London: Heinemann, 1992: 197-212
27. Willcox N, Schluep M, Ritter MA, et al. The thymus in séronégative myasthenia gravis patients. J Neurol 1991 ; 238: 256-61
28. Willcox N, Schluep M, Ritter MA, et al. Myasthenie and nonmyasthenic thymoma: an expansion of a minor cortical epithelial subset? Am J Pathol 1987; 127: 447-60
29. Sommer N, Willcox N, Harcourt GC, et al. Myasthenie thymus and thymoma are selectively enriched in acetylcholine receptor-reactive T cells. Ann Neurol 1990; 28: 312-9
30. Gunji K, Skolnick C, Bednarczuk T, et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol 1998:87:276-81
31. Hoch W, McConville J, Helms S, et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001; 7: 365-8
32. Bartoccioni E, Sauderi F, Evoli A, et al. Ocular myasthenia gravis: two different diseases. Lancet 1986; 1: 1038-9
33. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles. Clin Exp Immunol 1982; 49: 257-65
34. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody characteristics in myasthenia gravis. III. Patients with low anti-AChR antibody levels. Clin Exp Immunol 1985; 60:631-6
35. Wang ZY, Diethelm-Okita B, Okita DK, et al. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis. J Neuroimmunol 2000; 108: 29-39
36. Monden Y, Fujii Y, Masaoka A. Clinical characteristics of myasthenia gravis with other autoimmune diseases. Ann NY AcadSci 1987; 505: 876-8
37. Christensen PB, Jensen TS, Tsiropoulos I, et al. Associated autoimmune diseases in myasthenia gravis: a population-based study. Acta Neurol Scand 1995; 91: 192-5
38. Bergoffen J, Zmijewski CM, Fischbeck KH. Familial autoimmune myasthenia gravis. Neurology 1994; 44: 551-4
39. Kupersmith MJ, Moster M, Bhuiyan S, et al. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch Neurol 1996; 53: 802-4
40. Grob D, Arsura E, Brunner N, et al. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sei 1987; 505: 472-99
41. Bever CT, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Ann Neurol 1983; 14: 516-9
42. Oosterhuis HJGH. The ocular signs and symptoms of myasthenia gravis. Doc Ophthalmol 1982; 52: 363-78
43. Kaminski HJ, Maas E, Spiegel P, et al. Why are eye muscles frequently involved in myasthenia gravis? Neurology 1990; 40: 1663-9
44. Kaminski H. Treatment of ocular myasthenia. Arch Neurol 2000; 57: 752-3
45. Evoli A, Batocchi AP, Palmisani MT, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43
46. Agius MA. Treatment of ocular myasthenia with corticosteroids. Arch Neurol 2000; 57: 750-1
47. Pestronk A, Drachman DB, Self SG. Measurement of junctional acetylcholine receptors in myasthenia gravis: clinical correlates. Muscle Nerve 1985; 8: 245-51
48. Sanders DB, Howard Jr JF. Disorders of neuromuscular transmission. In: Bradley WG, Daroff RB, Fenichel GM, et al., editors. Neurology in clinical practice. Boston (MA): Butterworth-Heinemann, 2000: 2167-86
49. Johns TR. Long-term corticosteroid treatment of myasthenia gravis: Ann NY Acad Sei 1987; 505: 568-86
50. Saag K, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994; 96: 115-23
51. Caldwell JR, Fürst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 1-11
52. Hatz HJ, Helmke K. Polymyalgia rheumatica and giant cell arteritis: diagnosis and side effects of low-dose long-term glucocorticoid therapy. Z Rheumatol 1992; 51:213-21
53. Lloyd ME, Spector TD, Howard R. Osteoporosis in neurological disorders [editorial]. J Neurol Neurosurg Psychiatry 2000; 68: 543-9
54. Helfer EL, Rose LI. Corticosteroids and adrenal suppression: characterising and avoiding the problem. Drugs 1989; 38: 838-45
55. Cornelio F, Antozzi C, MantegazzaR, etal. Immunosuppressive treatments: their efficacy on myasthenia gravis patients' outcome and on the natural course of the disease. Ann NY Acad Sei 1993:681:594-603
56. Miano MA, Bosley TM, Heiman-Patterson TD, et al. Factors influencing outcome of prednisone dose reduction in myasthenia gravis. Neurology 1991; 41: 919-21
57. Palace J, Newsom-Davis J, Leckey B. A randomized doubleblind trial of prednisolone alone with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-83
58. Kokontis L, Gutmann L. Current treatment of neuromuscular diseases. Arch Neurol 2000; 57: 939-43
59. Witte AS, Cornblath DR, Parry GJ, et al. Azathioprine in the treatment of myasthenia gravis. Ann Neurol 1984; 15: 602-5
60. Hohlfeld R, Michels M, Heininger K, et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258-61
61. Kissel JT, Levy RJ, Mendell JR, et al. Azathioprine toxicity in neuromuscular disease. Neurology 1986; 36: 35-9
62. Mantegazza R, Antozzi C, Peluchetti D, et al. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol 1988; 235: 449-53
63. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 1018-24
64. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52
65. Asten P, Barren J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14
66. Kuks JB, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1991; 1: 423-31
67. Hohlfeld R, Toyka KV, Besinger UA, et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17:238-42
68. Buckingham JM, Howard FM, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer assisted matched study. Ann Surg 1976; 184: 453-7
69. Lanska DJ. Indications for thymectomy in myasthenia gravis. Neurology 1990; 40: 1828-9
70. Lindner A, Schalke B, Toyka KV. Outcome in juvenile-onset myasthenia gravis: a retrospective study with long-term follow-up of 79 patients. J Neurol 1997; 244: 515-20